

## Biden Administration Begins Building Infrastructure for Permanent Pandemic, DoD Signs \$137 Million Deal for Test Strip Facility to Complete in Late 2024

By **Sundance** 

Global Research, January 03, 2022

theconservativetreehouse.com

Theme: Global Economy, Police State & Civil Rights, Science and Medicine

The Biden administration is signaling that COVID-19, and all current and future variants therein, are part of the new and permanent way of life.

COVID-19 is being codified in the permanent regulatory state. The contracts for the continuance of the public health emergency supply procurements are coming through the Defense Department [Announcement Here]



Nitrocellulose membrane is a critical material used in manufacturing SARS-CoV-2 rapid point-of-care tests. This industrial base expansion effort will allow MilliporeSigma to establish a nitrocellulose manufacturing capability in its Sheboygan, Wisconsin facility to support more than 83.3 million tests per month for COVID-19 testing and future needs.

The DoD's Defense Assisted Acquisition Cell (DA2) led this effort in coordination with the Department of the Air Force's Acquisition COVID-19 Task Force (DAF ACT). This effort was funded through the American Rescue Plan Act (ARPA) to support domestic industrial base expansion for critical medical resources.

Many people feared that various government agencies, those who used the pandemic to gain raw power over U.S. citizens, would never relinquish their new authorities. This latest

announcement would indicate long term plans that are likely to end no sooner than when we stop taking off our shoes at the airport TSA checkpoints.

It's a smart Machiavellian move to use the DoD as the regulatory mechanism for the permanent state of emergency, as their spending authorities carry wide discretion and are supported by both wings of the UniParty and permanent security state, ie. The Fourth Branch of Government.

(<u>Via Daily Mail</u>) – The Biden administration struck a \$137 million deal to build a new factory in the U.S. to ramp up production of COVID-19 testing kits – but the new facility won't be completed until late 2024 at the earliest.

MilliporeSigma, a brand formed by Germany's Merck KGaA, will build a new factory in Sheboygan, Wisconsin, the Defense Department announced as the U.S. hit a high record of 489,267 COVID cases on Wednesday

While the contract gives the company three years to complete the facility, it is not immediately clear when it will ramp up to full production, which is expected to pump out 83.3 million tests per month.

'Construction is expected to begin the second half of 2022 and initial planning and preparatory work is already underway,' a MilliporeSigma spokesperson told DailyMail.com. 'We estimate that the facility will be capable of providing lateral flow membranes in the latter part of 2024.'

The individual said that the production of lateral flow membrane is 'critical for rapid diagnostic tests' that will not only help with COVID-19 detection, but also with 'any future public health emergencies.' (<u>read more</u>)

Once we get on their Ronacoaster, we can't get off until the ride's over. And apparently, if we let the government keep going, the ride is never over.

The original source of this article is <u>theconservativetreehouse.com</u> Copyright © <u>Sundance</u>, <u>theconservativetreehouse.com</u>, 2022

## **Comment on Global Research Articles on our Facebook page**

## **Become a Member of Global Research**

Articles by: Sundance

**Disclaimer:** The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: <a href="mailto:publications@globalresearch.ca">publications@globalresearch.ca</a>

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: <a href="mailto:publications@globalresearch.ca">publications@globalresearch.ca</a>